Neurofilament heavy chain has also been investigated as a potential biomarker in MS and levels appear to correlate with Expanded Disability Status Scale (EDSS) in patients with RRMS and clinically isolated syndrome (CIS) (n = 102), and also increased in patients with ongoing relapse (n = 61) (13). Here, NEFH is linked to in situ carcinoma.